Patents by Inventor Elizabeth Meyers
Elizabeth Meyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11788067Abstract: The present invention relates to a fusion protein consisting of a scFv linked to a horseradish peroxidase enzyme or to an alkaline phosphatase enzyme by a peptide linker. The fusion protein also includes a histidine tag and optionally an endoplasmic reticulum retention signal. The invention also includes nucleic acids encoding the fusion protein, expression vectors containing the nucleic acids, plant cells transformed with the expression vectors and methods of producing the fusion proteins of the invention.Type: GrantFiled: May 23, 2017Date of Patent: October 17, 2023Assignee: University of Cape TownInventors: Ann Elizabeth Meyers, Edward Peter Rybicki, Inga Isabel Hitzeroth
-
Publication number: 20230150931Abstract: Disclosed herein are FABP4 and FABP5 inhibitor compounds and their use in pharmaceutical compositions for treating diseases relating to fatty acid metabolism, including cancer. Also disclosed herein are methods for preparing the disclosed compounds.Type: ApplicationFiled: September 14, 2022Publication date: May 18, 2023Applicant: Novius Therapeutics, LLCInventors: Liraz Levi, Tej Pareek, Elizabeth Meyers, Seunghwan Lim, William J. Greenlee, Seong-Jin Kim
-
Patent number: 11555196Abstract: The present invention relates to a method for increasing the expression and/or promoting correct folding of a heterologous polypeptide of interest in a plant cell, comprising co-expressing the heterologous polypeptide of interest with a polypeptide encoding a mammalian chaperone protein. The invention also relates to plant cells and plants, which either transiently or stably, co-express the heterologous polypeptide of interest and the chaperone protein.Type: GrantFiled: June 1, 2018Date of Patent: January 17, 2023Assignee: UNIVERSITY OF CAPE TOWNInventors: Ann Elizabeth Meyers, Edward Peter Rybicki, Emmanuel Aubrey Margolin
-
Publication number: 20220280458Abstract: Compositions of matter and methods for applying the compositions to a skin surface for prevention of and treatment of bed sores as a foamed topical cleanser including about one part by volume of diluted acetic acid (5% (w/v) aqueous solution); about one part by volume of Aloe leaf juice; and about at least ¼ part by volume of body wash concentrate; with the proviso that the composition have a consistency such that, when foamed by a dispenser, running due to gravity is prevented for a period of time sufficient for the composition to dry or to accomplish cleansing and conditioning prior to towel drying.Type: ApplicationFiled: March 3, 2021Publication date: September 8, 2022Inventors: Margaret Elizabeth Meyers, Robert Michael Meyers, SR.
-
Publication number: 20220001352Abstract: A process for separations and recovery from mixtures via specific adsorption using high-surface area, flexible silica-based nanostructured gel adsorbents and articles of manufacture relating to same.Type: ApplicationFiled: July 2, 2021Publication date: January 6, 2022Applicant: UCHICAGO ARGONNE, LLCInventors: Patricia Ignacio de Leon, Philip D. Laible, Mackenzie Elizabeth Meyer, Christopher R. Povinelli, Killian L. Tracey, Daniel Yoav Arenas
-
Publication number: 20210388366Abstract: This invention relates to a second generation, plant-produced synthetic Orbivirus candidate vaccine. The vaccine comprises a plant produced chimaeric Orbivirus virus like particle (VLP) comprising at least one structural protein from one Orbivirus serotype and at least one structural protein selected from another serotype of the Orbivirus, wherein both structural capsid proteins are from the same Orbivirus species. In particular the invention relates to a vaccine against an Orbivirus, a method of producing chimaeric Orbivirus virus-like particles (VLPs) for use in a method of prevention and/or treatment of an Orbivirus infection, the use of the chimaeric Orbivirus VLPs in the manufacture of a vaccine for an Orbivirus, and a method of preventing and/or treating an Orbivirus infection.Type: ApplicationFiled: June 1, 2021Publication date: December 16, 2021Applicants: CSIR, UNIVERSITY OF CAPE TOWN, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC LTDInventors: Albertha René VAN ZYL, Ann Elizabeth MEYERS, Daria Anna RUTKOWSKA, Edward Peter RYBICKI, Hester Catharina STARK, Martha Magaretha O'KENNEDY, Nobalanda Betty MOKOENA
-
Patent number: 11053509Abstract: This invention relates to a second generation, plant-produced synthetic Orbivirus candidate vaccine. The vaccine comprises a plant produced chimaeric Orbivirus virus like particle (VLP) comprising at least one structural protein from one Orbivirus serotype and at least one structural protein selected from another serotype of the Orbivirus, wherein both structural capsid proteins are from the same Orbivirus species. In particular the invention relates to a vaccine against an Orbivirus, a method of producing chimaeric Orbivirus virus-like particles (VLPs) for use in a method of prevention and/or treatment of an Orbivirus infection, the use of the chimaeric Orbivirus VLPs in the manufacture of a vaccine for an Orbivirus, and a method of preventing and/or treating an Orbivirus infection.Type: GrantFiled: April 19, 2017Date of Patent: July 6, 2021Assignees: CSIR, UNIVERSITY OF CAPE TOWN, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC LTDInventors: Albertha René Van Zyl, Ann Elizabeth Meyers, Daria Anna Rutkowska, Edward Peter Rybicki, Hester Catharina Stark, Martha Magaretha O'Kennedy, Nobalanda Betty Mokoena
-
Patent number: 11052374Abstract: A process for separations and recovery from mixtures via specific adsorption using high-surface area, flexible silica-based nanostructured gel adsorbents and articles of manufacture relating to same.Type: GrantFiled: December 20, 2018Date of Patent: July 6, 2021Assignee: UChicago Argonne, LLCInventors: Patricia Ignacio de Leon, Philip D. Laible, Mackenzie Elizabeth Meyer, Christopher R. Povinelli, Killian L. Tracey, Daniel Yoav Arenas
-
Publication number: 20210147860Abstract: The present invention relates to a method for increasing the expression and/or promoting correct folding of a heterologous polypeptide of interest in a plant cell, comprising co-expressing the heterologous polypeptide of interest with a polypeptide encoding a mammalian chaperone protein. The invention also relates to plant cells and plants, which either transiently or stably, co-express the heterologous polypeptide of interest and the chaperone protein.Type: ApplicationFiled: June 1, 2018Publication date: May 20, 2021Inventors: Ann Elizabeth Meyers, Edward Peter Rybicki, Emmanuel Aubrey Margolin
-
Patent number: 10899801Abstract: The present invention relates to a method for producing a recombinant HIV glycoprotein polypeptide in a plant and to trimeric complexes of the recombinant, plant-produced HIV glycoprotein polypeptide which mimic the native HIV Env complex. The invention also relates to nucleic acids encoding the recombinant polypeptides, expression vectors containing the aforementioned nucleic acids and to pharmaceutical compositions, uses and methods of eliciting an immune response against HIV in a subject using the recombinant polypeptides and trimeric complexes.Type: GrantFiled: October 13, 2017Date of Patent: January 26, 2021Assignee: University of Cape TownInventors: Ann Elizabeth Meyers, Anna-Lise Williamson, Edward Peter Rybicki, Emmanuel Aubrey Margolin, Rosamund Chapman
-
Publication number: 20200339963Abstract: The present invention relates to a fusion protein consisting of a scFv linked to a horseradish peroxidase enzyme or to an alkaline phosphatase enzyme by a peptide linker. The fusion protein also includes a histidine tag and optionally an endoplasmic reticulum retention signal. The invention also includes nucleic acids encoding the fusion protein, expression vectors containing the nucleic acids, plant cells transformed with the expression vectors and methods of producing the fusion proteins of the invention.Type: ApplicationFiled: May 23, 2017Publication date: October 29, 2020Applicant: University of Cape TownInventors: Ann Elizabeth Meyers, Edward Peter Rybicki, Inga Isabel Hitzeroth
-
Publication number: 20200197900Abstract: A process for separations and recovery from mixtures via specific adsorption using high-surface area, flexible silica-based nanostructured gel adsorbents and articles of manufacture relating to same.Type: ApplicationFiled: December 20, 2018Publication date: June 25, 2020Applicant: UCHICAGO ARGONNE, LLCInventors: Patricia Ignacio de Leon, Philip D. Laible, Mackenzie Elizabeth Meyer, Christopher R. Povinelli, Killian L. Tracey, Daniel Yoav Arenas
-
Patent number: 10500361Abstract: A retention system for use with a bridle installed in a nose of a patient includes a member coupled to a medical device that is suspended from a nose of a patient and a connector for coupling to a bridle that is installed in a nose of a patient. The medical device extends into the mouth of a patient or is suspended adjacent the face of a patient.Type: GrantFiled: September 2, 2016Date of Patent: December 10, 2019Assignee: APPLIED MEDICAL TECHNOLOGY, INC.Inventors: Grant W. Phillips, Kathleen Walsh, Elizabeth A Meyer, Derek M. Williams, George J. Picha
-
Publication number: 20190337994Abstract: The present invention relates to a method for producing a recombinant HIV glycoprotein polypeptide in a plant and to trimeric complexes of the recombinant, plant-produced HIV glycoprotein polypeptide which mimic the native HIV Env complex. The invention also relates to nucleic acids encoding the recombinant polypeptides, expression vectors containing the aforementioned nucleic acids and to pharmaceutical compositions, uses and methods of eliciting an immune response against HIV in a subject using the recombinant polypeptides and trimeric complexes.Type: ApplicationFiled: October 13, 2017Publication date: November 7, 2019Inventors: Ann Elizabeth Meyers, Anna-Lise Williamson, Edward Peter Rybicki, Emmanuel Aubrey Margolin, Rosamund Chapman
-
Publication number: 20190136246Abstract: This invention relates to a second generation, plant-produced synthetic Orbivirus candidate vaccine. The vaccine comprises a plant produced chimaeric Orbivirus virus like particle (VLP) comprising at least one structural protein from one Orbivirus serotype and at least one structural protein selected from another serotype of the Orbivirus, wherein both structural capsid proteins are from the same Orbivirus species. In particular the invention relates to a vaccine against an Orbivirus, a method of producing chimaeric Orbivirus virus-like particles (VLPs) for use in a method of prevention and/or treatment of an Orbivirus infection, the use of the chimaeric Orbivirus VLPs in the manufacture of a vaccine for an Orbivirus, and a method of preventing and/or treating an Orbivirus infection.Type: ApplicationFiled: April 19, 2017Publication date: May 9, 2019Applicants: CSIR, UNIVERSITY OF CAPE TOWN, ONDERSTEPOORT BIOLOGICAL PRODUCTS SOC LTDInventors: Albertha René VAN ZYL, Ann Elizabeth MEYERS, Daria Anna RUTKOWSKA, Edward Peter RYBICKI, Hester Catharina STARK, Martha Magaretha O'KENNEDY, Nobalanda Betty MOKOENA
-
Patent number: 9622487Abstract: Formulations having a selective, mycoherbicide activity for killing ungerminated seeds of invasive grass species are provided. An agricultural, mycoherbicide formulation is taught for killing ungerminated seeds of invasive grass species. The formulations can comprise, for example, a slow-growing strain of Pyrenophora semeniperda, a fast-growing strain of Pyrenophora semeniperda, or a combination thereof, and an agriculturally acceptable carrier. As such, the teachings include a composition comprising a mixture of a slow-growing strain of Pyrenophora semeniperda and a fast-growing strain of Pyrenophora semeniperda. The mixture of strains can be used to provide a mixture of virulence that is useful for killing carryover seed banks, with regard to both type and level of virulence.Type: GrantFiled: July 27, 2012Date of Patent: April 18, 2017Assignees: The United States of America as Represented by the Secretary of Agriculture, Gonzaga UniversityInventors: Susan Elizabeth Meyer, Suzette Clement, Julie Beckstead
-
Patent number: 9555097Abstract: An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.Type: GrantFiled: October 9, 2009Date of Patent: January 31, 2017Assignee: ERA BIOTECH, S.A.Inventors: Edward Peter Rybicki, Ann Elizabeth Meyers, François Devesa, Pablo Marzábal Luna, Inga Isabel Hitzeroth, Peter Öhlschläger
-
Publication number: 20160367777Abstract: A retention system for use with a bridle installed in a nose of a patient includes a member coupled to a medical device that is suspended from a nose of a patient and a connector for coupling to a bridle that is installed in a nose of a patient. The medical device extends into the mouth of a patient or is suspended adjacent the face of a patient.Type: ApplicationFiled: September 2, 2016Publication date: December 22, 2016Inventors: Grant W. Phillips, Kathleen Walsh, Elizabeth A Meyer, Derek M. Williams, George J. Picha
-
Publication number: 20160243213Abstract: An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence.Type: ApplicationFiled: October 9, 2009Publication date: August 25, 2016Applicant: Era Biotech, S.A.Inventors: Edward Peter Rybicki, Ann Elizabeth Meyers, François Devesa, Pablo Marzábal Luna, Inga Isabel Hitzeroth, Peter Öhlschläger
-
Patent number: D862707Type: GrantFiled: December 1, 2017Date of Patent: October 8, 2019Assignee: TS Medical Products, LLCInventors: Tina Lynn Roelse, Sara Elizabeth Meyer